ERBB2 and breast carcinoma: The expression of constitutively active, standard immunotherapy treatment (trastuzumab and pertuzumab) resistant, truncated p95-ErbB2 in breast cancer cells activates macropinocytosis leading to increased uptake of extracellular cholesterol.